IDEV Technologies Launches Lower Profile SUPERA VERITAS® Stent Delivery System
Share:
Improved Operation and Control Make Stent Delivery More Efficient and Predictable
WEBSTER, Texas - IDEV Technologies, Incorporated (IDEV), today announced the first procedures in Europe utilizing the new 6 French (6Fr) SUPERA VERITAS® Peripheral Vascular System. The new lower profile delivery system offers physicians more treatment options, easier operation, and greater delivery control, while providing the unique strength, flexibility, and performance benefits of the SUPERA stent.
The 6Fr size allows a smaller access site and multiple approach options when treating patients with peripheral artery disease (PAD), which can be particularly important when treating stenoses or occlusions in the superficial femoral artery (SFA) and the popliteal artery. In addition to having a lower entry profile, the new 6Fr system is available in two catheter lengths, 80 cm and 120 cm, and offers even better efficiency and trackability.
Initial procedures were done last month at Canisius-Wilhelmina Ziekenhuis (CWZ) in Nijmegen, Netherlands and also at three German sites: Park Hospital in Leipzig, Heart Centre Bad Krozingen, and University Hospital in Heidelberg. Feedback from the treating physicians has been enthusiastic.
"The new 6Fr system allowed for better control of stent deployment while requiring less force to deliver," commented Andrej Schmidt, MD, PhD, at the Park Hospital. "In addition, the modified outer sheath easily tracked through tortuous anatomy. Over the years, IDEV has continued to refine the stent delivery system to provide greater utility and flexibility to physicians."
Dr. Sebastian Sixt of Herz Zentrum (Heart Centre) Bad Krozingen stated, "I appreciate how easily I can control the stent delivery. The improved delivery makes it very straightforward to predict the stent landing zone, and treat the lesion appropriately."
Dr. Peter Haarbrink of CWZ and Dr. Erwin Blessing at Heidelberg agree the lower profile 6Fr system offers the benefits of the SUPERA stent to portions of the market that were not previously served. Dr. Haarbrink elaborated, "Many of our procedures utilize 6Fr systems, so having SUPERA VERITAS now available in this size allows us to use our stent of choice without switching to a different sheath."
"Launching the lower profile SUPERA VERITAS system was a key corporate milestone this year," commented Christopher M. Owens, President and CEO of IDEV. "We are committed to meeting customer needs and working closely with physicians to provide products that are truly differentiated. This is another example of the Company investing in research and ongoing development to deliver patient benefits."
A full launch of the lower profile 6Fr SUPERA VERITAS Peripheral Vascular System will occur this summer throughout Europe.
About IDEV Technologies, Incorporated
IDEV Technologies, Incorporated (IDEV) is an innovator and developer of next generation medical devices for use in interventional radiology, vascular surgery and cardiology. IDEV's worldwide headquarters is located in Webster, Texas and its European headquarters is located in Beuningen, The Netherlands.
The SUPERA stent is currently indicated in the United States for the palliative treatment of biliary strictures produced by malignant neoplasms and in Europe, Canada and Australia for the treatment of biliary strictures produced by malignant neoplasms and for peripheral vascular use following failed percutaneous transluminal angioplasty (PTA).
For more information please visit www.idevmd.com.
Contact:
Donna Lucchesi
Vice President Global Marketing
IDEV Technologies, Incorporated
(281) 525-2000
SOURCE
IDEV Technologies, Incorporated
Web Site: www.idevmd.com
